BioWorld

July 13, 2005

Genentech Tallies Another Quarter Of Strong Earnings

Like a broken record playing a song investors never tire of hearing, Genentech Inc. chalked up another satisfying quarter, with Avastin and Herceptin sales benefiting from a parade of positive news this spring. (BioWorld Today) Read More

Pharmacopeia, Allergan Enter Agreement For Wet AMD Drugs

From In Vivo Research Come Insights Into P53 Regulation

Nabi's StaphVAX Phase II Trial Confers Lofty Immunity Levels

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...